These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11182231)

  • 1. Association between high serum prolactin levels and concomitant infections in HIV-infected patients.
    Montero A; Bottasso OA; Luraghi MR; Giovannoni AG; Sen L
    Hum Immunol; 2001 Feb; 62(2):191-6. PubMed ID: 11182231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Gonzalez C; McMahon D; Richman DD; Valentine FT; Jonas L; Meibohm A; Emini EA; Chodakewitz JA
    N Engl J Med; 1997 Sep; 337(11):734-9. PubMed ID: 9287228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV-infected men are associated with CD4+ T-lymphocytes.
    Parra A; Reyes-Terán G; Ramírez-Peredo J; Jacquemin B; Quiroz V; Cárdenas M; García-Sancho MC; Larrea F
    Immunol Cell Biol; 2004 Feb; 82(1):24-31. PubMed ID: 14984591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hyperprolactinemia is a frequent finding in HIV infection but does not correlate with viral burden].
    Montero A; Giovannoni AG; Sen L
    Medicina (B Aires); 2000; 60(4):427-30. PubMed ID: 11188945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
    Havlir DV; Marschner IC; Hirsch MS; Collier AC; Tebas P; Bassett RL; Ioannidis JP; Holohan MK; Leavitt R; Boone G; Richman DD
    N Engl J Med; 1998 Oct; 339(18):1261-8. PubMed ID: 9791141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
    Jankelevich S; Mueller BU; Mackall CL; Smith S; Zwerski S; Wood LV; Zeichner SL; Serchuck L; Steinberg SM; Nelson RP; Sleasman JW; Nguyen BY; Pizzo PA; Yarchoan R
    J Infect Dis; 2001 Apr; 183(7):1116-20. PubMed ID: 11237839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
    Sölder B; Wintergerst U; Notheis G; Eberle J; Gürtler L; Belohradsky BH
    J Pediatr; 1997 Feb; 130(2):293-9. PubMed ID: 9042135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs.
    Rockstroh JK; Theisen A; Kaiser R; Sauerbruch T; Spengler U
    AIDS; 1998 May; 12(7):829-30. PubMed ID: 9619824
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
    Pialoux G; Raffi F; Brun-Vezinet F; Meiffrédy V; Flandre P; Gastaut JA; Dellamonica P; Yeni P; Delfraissy JF; Aboulker JP
    N Engl J Med; 1998 Oct; 339(18):1269-76. PubMed ID: 9791142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
    Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
    AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
    Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
    Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS?
    Ceballos-Salobreña A; Gaitán-Cepeda LA; Ceballos-Garcia L; Lezama-Del Valle D
    AIDS Patient Care STDS; 2000 Dec; 14(12):627-35. PubMed ID: 11119429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
    Gulick RM; Mellors JW; Havlir D; Eron JJ; Meibohm A; Condra JH; Valentine FT; McMahon D; Gonzalez C; Jonas L; Emini EA; Chodakewitz JA; Isaacs R; Richman DD
    Ann Intern Med; 2000 Jul; 133(1):35-9. PubMed ID: 10877738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum prolactin concentrations in patients infected with human immunodeficiency virus.
    Collazos J; Ibarra S; Martínez E; Mayo J
    HIV Clin Trials; 2002; 3(2):133-8. PubMed ID: 11976991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.
    Wintergerst U; Hoffmann F; Sölder B; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH
    Pediatr Infect Dis J; 1998 Jun; 17(6):495-9. PubMed ID: 9655541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of natural killer cell and T-lymphocyte counts in adults infected with human immunodeficiency virus through blood and plasma sold in the past in China and in whom infection has progressed slowly over a long period.
    Jiang Y; Shang H; Zhang Z; Diao Y; Dai D; Geng W; Zhang M; Han X; Wang Y; Liu J
    Clin Diagn Lab Immunol; 2005 Nov; 12(11):1275-9. PubMed ID: 16275940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.